Autolus Therapeutics Q1 2025 10-Q Filed

Ticker: AUTL · Form: 10-Q · Filed: 2025-05-08T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

Autolus Q1 2025 10-Q is in: financials and share details updated.

AI Summary

Autolus Therapeutics plc filed its 10-Q for the period ending March 31, 2025. The company, focused on biological products, reported financial data for the first quarter of 2025. Key financial instruments and share classes, including Ordinary Shares, Deferred Class A, B, and C Shares, were detailed. The filing also included information on product-related activities for the first quarters of 2025 and 2024.

Why It Matters

This filing provides investors with the latest financial snapshot of Autolus Therapeutics, crucial for understanding their operational and financial health in early 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new disclosures.

Key Numbers

2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter covered by the report.)
2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
2025-01-01 — Reporting Period Start Date (Marks the beginning of the financial quarter.)

Key Players & Entities

Autolus Therapeutics plc (company) — Filer of the 10-Q
20250331 (date) — End of the reporting period
20250508 (date) — Filing date
OrdinarySharesMember (financial_instrument) — Class of shares reported
DeferredClassASharesMember (financial_instrument) — Class of shares reported

FAQ

What is the primary business of Autolus Therapeutics plc?

Autolus Therapeutics plc is primarily involved in the biological products sector, specifically focusing on biological products (no diagnostic substances).

What is the SEC file number for Autolus Therapeutics plc?

The SEC file number for Autolus Therapeutics plc is 001-38547.

What period does this 10-Q filing cover?

This 10-Q filing covers the period ending March 31, 2025.

When was Autolus Therapeutics plc incorporated or formed?

The filing indicates the company was formerly known as Autolus Therapeutics Ltd and the date of the name change was February 5, 2018.

What are the different classes of shares mentioned in the filing?

The filing mentions Ordinary Shares, Deferred Class A Shares, Deferred Class B Shares, and Deferred Class C Shares.

From the Filing

0001730463-25-000039.txt : 20250508 0001730463-25-000039.hdr.sgml : 20250508 20250508161220 ACCESSION NUMBER: 0001730463-25-000039 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 97 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 25926219 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 10-Q 1 autl-20250331.htm 10-Q autl-20250331 0001730463 false 2025 Q1 12/31 True xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:GBP xbrli:shares xbrli:pure autl:financialInstrument autl:performanceObligation autl:security autl:vote autl:payment autl:director 0001730463 2025-01-01 2025-03-31 0001730463 dei:AdrMember 2025-01-01 2025-03-31 0001730463 autl:OrdinarySharesMember 2025-01-01 2025-03-31 0001730463 2025-05-07 0001730463 2025-03-31 0001730463 2024-12-31 0001730463 autl:OrdinarySharesMember 2024-12-31 0001730463 autl:OrdinarySharesMember 2025-03-31 0001730463 autl:DeferredClassASharesMember 2024-12-31 0001730463 autl:DeferredClassASharesMember 2025-03-31 0001730463 autl:DeferredClassBSharesMember 2025-03-31 0001730463 autl:DeferredClassBSharesMember 2024-12-31 0001730463 autl:DeferredClassCSharesMember 2025-03-31 0001730463 autl:DeferredClassCSharesMember 2024-12-31 0001730463 us-gaap:ProductMember 2025-01-01 2025-03-31 0001730463 us-gaap:ProductMember 2024-01-01 2024-03-31 0001730463 us-gaap:LicenseMember 2025-01-01 2025-03-31 0001730463 us-gaap:LicenseMember 2024-01-01 2024-03-31 0001730463 2024-01-01 2024-03-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2024-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassBSharesMember 2024-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2024-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001730463 us-gaap:RetainedEarningsMember 2024-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2025-01-01 2025-03-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001730463 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2025-03-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2025-03-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassBSharesMember 2025-03-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2025-03-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001730463 us-gaap:RetainedEarningsMember 2025-03-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassBSharesMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2023-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001730463 us-gaap:RetainedEarningsMember 2023-12-31 0001730463 2023-12-31 0001730463 us-gaap:CommonStockMemb